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Abstract  96 
Objective  97 
We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D).  98 
Research Design and Methods  99 
732 recently diagnosed T2D patients from the IMI-DIRECT study were extensively phenotyped 100 
over three years, including measures of insulin sensitivity (OGIS), β-cell glucose sensitivity (GS) 101 
and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline 102 
regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA1c 103 
deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise 104 
multivariable linear and logistic regression.  105 
Results 106 
Faster HbA1c progression was independently associated with faster deterioration of OGIS and GS, 107 
and increasing CLIm; visceral or liver fat, HDL-cholesterol and triglycerides had further 108 
independent, though weaker, roles (R2=0.38). A subgroup of patients with a markedly higher 109 
progression rate (fast progressors) was clearly distinguishable considering these variables only 110 
(discrimination capacity from AUROC=0.94). The proportion of fast progressors was reduced from 111 
56% to 8-10% in subgroups in which only one trait among OGIS, GS and CLIm was relatively 112 
stable (odds ratios 0.07 to 0.09). T2D polygenic risk score and baseline pancreatic fat, GLP-1, 113 
glucagon, diet, and physical activity did not show an independent role.  114 
Conclusions 115 
Deteriorating insulin sensitivity and β-cell function, increasing insulin clearance, high visceral or 116 
liver fat, and worsening of the lipid profile are the crucial factors mediating glycemic deterioration 117 
 
 
of T2D patients in the initial phase of the disease. Stabilization of a single trait among insulin 118 
sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression.  119 
 
 
Maintaining glucose levels within appropriate limits in patients with type 2 diabetes (T2D) is a 120 
crucial factor to prevent complications. Effective strategies to slow glycemic progression can be 121 
supported by understanding the processes underlying deterioration of glucose control.  122 
Few studies have assessed HbA1c trajectories and the possible determinants of glycemi  123 
deterioration. An established finding is that β-cell function decline is an important factor (1,2), 124 
while contradictory conclusions were drawn for insulin sensitivity (1,3–7). Whether heterogeneous 125 
patterns between patients exist in β-cell function and insulin sensitivity decline has not been 126 
clarified, an important question for patient stratification and personalized medicine. Other 127 
limitations of previous analyses include the incomplete characterization of the metabolic parameters 128 
affecting glucose homeostasis (derived using fasting data only (2,4)), the restricted set of traits 129 
investigated together, and the lack of potentially re evant measures such as ectopic fat, insulin 130 
clearance, or lifestyle. No study has assessed the relationships between the longitudinal trajectories 131 
of HbA1c and those of the other metabolic traits.  132 
In this analysis, we have used data from the cohort of recently diagnosed and extensively 133 
phenotyped T2D patients of the DIRECT study (8,9) to elucidate the processes underlying glycemic 134 
deterioration. Specific features of the DIRECT study are the detailed assessment of the glucose 135 
homeostasis parameters, and patients all being in the initial phase of the disease. We determined the 136 
patterns over a 3-year period of HbA1c, β-cell function, insulin sensitivity and other relevant 137 
laboratory, clinical and functional parameters, andssessed their relevance in the deterioration of 138 
glucose control.  139 
Research Design and Methods  140 
Subjects and protocol  141 
The IMI-DIRECT (Innovative Medicines Initiative - Diabetes Research on Patient Stratification) 142 
project is a multicenter prospective study on northern European adults (8,9) (ClinicalTrials.gov 143 
 
 
identifier NCT03814915). The present analysis consider  the DIRECT cohort of recently diagnosed 144 
T2D patients, who were recruited according to the following criteria: white race, T2D diagnosis 145 
according to the American Diabetes Association 2011 criteria (10) not less than 6 months and not 146 
more than 24 months before baseline examination, previous treatment via lifestyle measures with or 147 
without metformin therapy, age between 35 and 74 years, BMI between 20 and 50 kg/m2, estimated 148 
glomerular filtration rate >50 ml/min, and HbA1c concentration <7.64 % (60.0 mmol/mol) within 149 
the previous 3 months. Participants were studied at baseline (month 0) and at months 9, 18 and 36. 150 
Subjects with HbA1c available at least in two visits were included in this analysis (N=750).  151 
All participants provided written informed consent a d the study protocol was approved by the 152 
regional research ethics review boards. The research conformed to the ethical principles for medical 153 
research involving human participants outlined in the declaration of Helsinki.  154 
Collected data  155 
Anthropometric data, HbA1c, blood lipids and liver enzymes were collected at all visits. A 27-month 156 
HbA1c sample was collected in 39 patients. A standardized mixed meal test (8) (MMTT) was 157 
performed at months 0, 18 and 36 to calculate indices of insulin sensitivity (in fasting conditions, 158 
QUICKI (11), and post-MMTT, OGIS (12)), β-cell function (13) (glucose sensitivity, GS, and rate 159 
sensitivity), and insulin clearance (in fasting conditions, and post-MMTT, CLIm). From the 160 
baseline visit we collected glucagon, proinsulin and glucagon-like peptide 1 (GLP-1), measures of 161 
regional fat from MRI (8) (available in 561 participants), of physical activity from accelerometer 162 
(8), and of self-reported 24-hour nutrient intake (8), and we computed the fatty liver index (FLI) 163 
(14) and a T2D polygenic risk score (PRS) (15). Thew ole set of traits considered in this study is 164 
described in detail in the Supplemental Material (DATA, METHODS, and Table S2).  165 
Assessment of progression rates  166 
 
 
We computed the progression rates for HbA1c and several traits available at follow up 167 
(Supplemental Table S4). Each trajectory was described with a conditional linear mixed-effect 168 
model (16), in which the longitudinal component of he data was described as a proportional 169 
function of time, with normally distributed slopes describing individual progression rates. HbA1c 170 
progression was adjusted for changes in BMI and diabetes medications, which were recorded at all 171 
visits (as dosage and start and end of treatment). The adjustments were assumed to be 1) 172 
proportional to BMI; 2) linearly related to the metformin dose, expressed as percentage of a 173 
maximal dose of 3 grams; 3) linearly related to the cumulative dose for the other antidiabetic drugs 174 
(insulin excluded), expressed as sum of the percentag s of the maximum dose of each drug; 4) 175 
constant under insulin treatment. A proportional effect of delay in HbA1c assay, i.e. of the difference 176 
between the time of measurement and the time of sample collection, was also introduced. 177 
Medications were considered to be effective if taken at least 30 days before HbA1c measurement. 178 
OGIS and QUICKI trajectories were adjusted for changes in BMI. Further details about the 179 
conditional linear mixed-effect models are provided in the Supplemental Material (METHODS).  180 
Statistical analysis  181 
Results are presented for participants (N=732) with GAD <11 U/ml and islet antigen-2 antibodies 182 
(IA-2) <7.5 U/ml, to exclude other possible forms of diabetes (17). Distributions are described as 183 
mean ± standard deviation. Pairwise associations between continuous variables were assessed using 184 
the Spearman correlation coefficient; differences btween groups were assessed using the Wilcoxon 185 
signed rank test (for two groups) and Kruskal-Wallis test (for three or more groups).  186 
We used stepwise multivariable linear regression to determine the set of variables, as baseline 187 
values (Table S2) and progression rates (Table S4), independently associated with the HbA1c 188 
progression rate, with adjustment for center, sex and age. For baseline variables, both 189 
untransformed and transformed values were considered; transformations were logarithmic, or logit 190 
when variables where constrained within an interval. The independent variables were included in 191 
 
 
the regression model when their effects had p<0.05 and produced an increment in the adjusted R2 192 
value. Two stepwise analyses were performed: one on all participants, excluding MRI variables 193 
from the analysis, and one on the subset of participants with MRI data, including this data in the 194 
analysis. Standardized coefficients were computed per standard deviation of the underlying data 195 
distribution. 196 
Since the distribution of HbA1c progression rates was skewed to the right with a group of patients 197 
with high values, we split the subjects into average and fast progressors according to a progression 198 
rate threshold (see Results). We used multivariable logistic regression to assess the odds ratios of 199 
average vs fast progression, using the independent variables identified in the multiple linear 200 
regression analysis of HbA1c progression. The logistic analysis provided values for AUROC, 201 
sensitivity, specificity and accuracy, to be used as measures of the discrimination capacity of the 202 
investigated independent variables over fast vs average progressors. These parameters must not be 203 
interpreted as measures of predictive capacity. 204 
Role of the funding source  205 
The funders had no role in study design, in collection, analysis, and interpretation of data, in writing 206 
of the report, or in the decision to submit the paper for publication. The corresponding author had 207 
full access to all data and had final responsibility for the decision to submit for publication.  208 
Results  209 
Subjects’ baseline characteristics  210 
At baseline, the participants had age of 62±8 years, were moderately obese (30.4±4.9 kg/m2 BMI), 211 
and had HbA1c of 6.41±0.53 % (46.5±5.8 mmol/mol) and fasting glucose of 7.1±1.4 mmol/l. (Table 212 
S2). 34% of the subjects were treated with metformin at baseline, the rest was treatment naïve.  213 
Progression rates of HbA1c and other traits  214 
 
 
The individual HbA1c progression rates (Supplemental Figure S1), adjusted for changes in BMI and 215 
in diabetes medications, were on average only slightly positive and mostly distributed close to their 216 
median (median, first and ninth deciles were 0.041, -0.038 and 0.185 %/year (0.45, -0.41 and 2.02 217 
mmol mol-1 year-1), respectively). However, the distribution showed a heavy right tail with values 218 
up to 0.897 %/year (9.8 mmol mol-1 year-1). The adjustment of progression rates for BMI changes 219 
implied a standardized coefficient for the BMI effect of 0.37.  220 
All the other investigated traits had a mean progression rate per year smaller, in absolute value, than221 
5% of the corresponding baseline average (see Table S5 for details). On average, waist 222 
circumference, but not BMI, increased very slightly. Insulin sensitivity (as OGIS) and most of the 223 
β-cell function parameters decreased. Fasting, but not post-meal, insulin clearance decreased. Total 224 
cholesterol did not change, while its fractions showed opposite changes, with HDL increasing and 225 
LDL decreasing; TG increased. Creatinine and ALT did not change, while AST and AST/ALT 226 
increased.  227 
Several pairwise associations were observed between HbA1c progression rate and laboratory, 228 
clinical, and functional parameters (Supplemental Figure S2). In particular, HbA1c progression rate 229 
was clearly associated (p<0.01) with some baseline traits (positively with BMI, waist 230 
circumference, triglycerides, glucagon, liver and visceral fat; inversely with age, HDL, insulin 231 
sensitivity, and β-cell function) and some progression rates (positively with those of triglycerides 232 
and liver enzymes; inversely with those of insulin sensitivity, β-cell function, AST/ALT ratio, and 233 
HDL).  234 
Several pairwise associations were also observed between the progression rates of the investigated 235 
traits (Figure S2, panel B). GS and OGIS progression rates were independent of one another despite 236 
HbA1c progression rate being associated with both of them.  237 
Variables associated with HbA1c progression rate: multivariable linear analysis  238 
 
 
In multivariable linear analysis of HbA1c progression rate in all patients, the baseline values and the 239 
progression rates of several traits provided an independent contribution (adjusted R2 0.38; Figure 1, 240 
panel A). Faster HbA1c progression was independently associated with lower baseline values and 241 
faster deterioration of insulin sensitivity (as OGIS) and β-cell function (mostly as glucose 242 
sensitivity, GS), with higher baseline values of MMTT insulin clearance, CLIm, and with its 243 
increase (all p-values <0.001). Faster HbA1c progression was also independently associated with 244 
lower baseline HDL (p<0.05) or its slower increase (p<0.001), with a quicker increase of TG 245 
(p<0.001), as well as with higher baseline values of BMI (p<0.01) and lower baseline values of 246 
HbA1c (p<0.001). The variables with strongest effects were the baseline OGIS value and the 247 
progression rates of OGIS, GS and CLIm (standardized co fficients, in absolute value, between 248 
0.24 and 0.57).  249 
In multivariable analysis of the subset of patients with baseline MRI measurements (adjusted R2 250 
0.40; Figure 1, panel B), baseline visceral fat waspo itively and independently correlated with 251 
HbA1c progression rate; moreover, female sex and younger age independently predicted faster 252 
HbA1c progression. The role of the other key metabolic parameters, OGIS, GS and CLIm, remained 253 
similar. Replacing visceral fat with liver fat produced similar results (standardized coefficient equal 254 
to 0.15 for visceral fat, to 0.11 for liver fat); when both visceral and liver fat were included in the 255 
model, the latter was not independently associated with HbA1c progression.  256 
No independent effects were detected for smoking statu , family history, T2D polygenic risk score, 257 
baseline values of diet, physical activity, pancreatic f t, GLP-1 (total and intact at fasting, total at 60 258 
min), glucagon, and 60-min proinsulin, baseline values and progression rates of AST and ALT.  259 
Further details on the multivariable linear analysis are reported in the Supplemental Material 260 
(RESULTS).  261 
Variables associated with HbA1c progression rate: multivariable logistic analysis  262 
 
 
The threshold selected to separate the heavy right tail of the distribution of HbA1c progression rates 263 
was 0.255 %/year (2.79 mmol mol-1 year-1). This threshold split the subjects into average 264 
progressors (N=699), with a progression rate of 0.044±0.076 %/year (0.48±0.83 mmol mol-1 year-1), 265 
and fast progressors (N=33), with a ~10-fold mean progression rate (0.460±0.185 %/year, 266 
5.03±2.02 mmol mol-1 year-1) (Figure 2).  267 
We found that the trajectories of most variables independently affecting HbA1c progression as from 268 
the linear analysis were clearly different (p<0.001) in the two groups (Figure 2): in fast progressors, 269 
OGIS and GS strongly declined and TG and CLIm markedly increased. At baseline, fast 270 
progressors had lower OGIS (p<0.05), CLIm (p<0.01) and HDL (p<0.001), and higher BMI 271 
(p<0.01).  272 
Logistic analysis substantially confirmed the results of linear regression (Figure 1), with half the 273 
investigated variables still contributing (p<0.05) to distinguish average and fast progressors (Figure 274 
3): fast HbA1c progression independently associated with stronger deterioration and a lower 275 
baseline value of OGIS and GS, CLIm increase, and HDL reduction. The discrimination capacity of 276 
the logistic model, computed as AUROC, was 0.94 (95% CI between 0.86 and 0.98).  277 
Similar outcomes were obtained using lower HbA1c progression rate thresholds, which resulted in 278 
larger numbers of patients classified as fast progressors (Supplemental Material - RESULTS, 279 
Figures S1 and S3).  280 
At baseline, the percentage of patients treated with metformin were not different between fast 281 
progressors (39.4% [24.7-56.3%, 95% CI]) and average progressors (33.9% [30.5-37.5%], p = 282 
0.64). At the last visit, the percentage of patients treated with any diabetes medication was 283 
somewhat higher in fast progressors, as expected (p = 0.048, details provided in the Supplemental 284 
Material - RESULTS). Only 7 average progressors were on insulin at the last visit. 285 
Impact of stable OGIS, GS or CLIm on proportion of fast HbA1c progressors  286 
 
 
Because HbA1c progression was associated with worsening of three main factors, OGIS, GS and 287 
CLIm, we have evaluated the possible importance of maintaining one of these key traits relatively 288 
stable in order to avoid fast progression. For this purpose, we considered each trait as deteriorating 289 
if its progression rate fell within its worst tertile (the bottom tertile for OGIS and GS, the top one290 
for CLIm), and as stable if it fell in the other two tertiles. We examined the subgroups of patients in 291 
which none or only one of these key traits was relatively stable (Table 1).  292 
We found that the proportion of fast progressors wa56% in the patient subgroup where GS, OGIS 293 
and CLIm were all deteriorating, and decreased to 8-10% in the subgroups where a single trait, 294 
either GS, OGIS or CLIm, was stable. All proportions were different from 0 at 90% confidence 295 
level, stressing that fast progression did not imply quick changes for each of the three considered 296 
traits. All differences in proportions (one stable trait vs none) had p<0.001, and were associated to 297 
odds ratio for fast vs average progression below 0.1 (Table 1); thus, relativ ly stable progression 298 
rate of one single trait among GS, OGIS and CLIm was strongly associated to reduced glycemic 299 
deterioration.  300 
Conclusions  301 
Leveraging on the detailed participant characterization of the DIRECT study, we have been able to 302 
elucidate the processes underlying glycemic deterioration in T2D patients in the initial phase of the 303 
disease. We found that HbA1c deterioration was independently associated with 1) a decrease in 304 
insulin sensitivity; 2) a decrease in β-cell function (primarily β-cell glucose sensitivity); 3) an 305 
increase in insulin clearance; 4) lower values of insulin sensitivity and glucose sensitivity and 306 
higher values of insulin clearance at baseline. Further variables independently associated with faster 307 
HbA1c progression were declining HDL, increasing TG and high baseline visceral or liver fat.  308 
The variables identified by multivariable linear analysis also explained the rapid HbA1c 309 
deterioration detected in a subset of patients (ident fi d as fast progressors), the strongest predicting 310 
variables of the multivariable linear model being significant also with logistic analysis. Clear 311 
 
 
differences were evident between fast and average HbA1c progressors (Figure 2), consistent with the 312 
associations derived from the multivariable linear analysis. The high discrimination capacity of the 313 
logistic analysis suggests that the selected variables capture the most relevant pathophysiological 314 
factors underlying glycemic deterioration.  315 
The independent associations with HbA1c progression of several variables, in particular the 316 
progression rates of insulin sensitivity, β-cell function and insulin clearance, and the existnce of 317 
fast HbA1c progressors with relatively stable conditions for any of these three traits (Table 1), 318 
indicates 1) that the processes of glycemic deterioration are heterogeneous in this population of 319 
T2D patients; 2) that fast progression does not imply quick deterioration of a specific trait, e.g. 320 
insulin sensitivity or β-cell function.  321 
The dichotomous analysis shows that the odds for fast vs average progression are substantially 322 
reduced when either glucose sensitivity, insulin sensitivity or insulin clearance is relatively stable. 323 
Although these findings do not demonstrate causality, they suggest that preventing either high 324 
degradation rates of glucose sensitivity or insulin se sitivity, or high increase rates of insulin 325 
clearance, may be an effective strategy to slow down glycemic deterioration in the initial phase of 326 
the disease. This reemphasizes the importance of lifestyle interventions aiming at controlling insulin 327 
resistance, as preventing deterioration of the other traits currently appears more difficult.  328 
This study also shows that insulin resistance plays a major role in glycemic deterioration in these 329 
T2D patients. In particular, we show associations of glycemic deterioration with baseline insulin 330 
sensitivity and its longitudinal change that the Belfast Diet Study (1), UKPDS (4,18) and ADOPT 331 
(6) could not identify, possibly due to differences in subject selection or to the use of post-MMTT 332 
vs fasting insulin sensitivity indices. We also demonstrate that the associations between glycemic 333 
deterioration and insulin sensitivity are independent from both the baseline value and the 334 
progression rate of the β-cell function, and that insulin resistance progresses independently from β-335 
cell glucose sensitivity. Since in our analysis both HbA1c and insulin sensitivity trajectories were 336 
 
 
adjusted for BMI changes and BMI did not increase on average, we can conclude that worsening of 337 
insulin resistance in T2D and the associated glycemi  deterioration are partly independent from 338 
BMI changes. Whether the observed average increases in TG and AST (whose progression rates 339 
were inversely correlated with OGIS progression rate) have a role in insulin sensitivity deterioration 340 
(19), and whether this is mediated by ectopic fat accumulation (20), deserves further study.  341 
UKPDS 25 and 26 (4,18), the Belfast Diet Study (1) and the ADOPT study (6) identified baseline 342 
HOMA-%B as a predictor of glycemic deterioration (isulin requirement within 6 years for 343 
UKPDS, time of failure to dietary therapy for the Blfast Diet Study, and monotherapy failure 344 
before 4 years for ADOPT). Our study confirms the rol  of β-cell dysfunction as driver of glycemic 345 
deterioration using a dynamic β-cell function assessment based on a glucose challenge, rather than 346 
on fasting data only. We show that both baseline β-c ll dysfunction (especially β-cell glucose 347 
sensitivity) and its deterioration over time are independently associated with HbA1c worsening. 348 
Moreover, we demonstrate that patients with limited or absent deterioration in β-cell function have 349 
considerably lower odds of rapid glycemic deteriorati n.  350 
Another novel finding is the strong and independent association between HbA1c progression and 351 
insulin clearance during the MMTT, CLIm. To our knowledge, this is the first study examining 352 
insulin clearance trajectories after T2D onset. We found that higher baseline CLIm and faster CLIm 353 
increase over time independently associate with faster HbA1c progression. This is consistent with 354 
the glucose homeostasis mechanisms, as higher CLIm reduces the average insulin levels. Notably, 355 
we found a positive correlation between insulin sensitivity and insulin clearance, considering both 356 
the baseline values of the two traits, in agreement with previous findings (21), and their progression 357 
rates (Figure S2). However, on average, in spite of a decrease in insulin sensitivity, insulin 358 
clearance did not decrease. These findings show that, w ile in pre-diabetic subjects insulin 359 
clearance reduction may be a way to mitigate the effects of insulin resistance (22), in T2D patients 360 
this compensation appears present but impaired and co tributing to glycemic deterioration. The 361 
 
 
reasons underlying these results remain elusive. Th lack of decrease in insulin clearance may be 362 
explained by the decrease of total MMTT insulin secretion and consequent desaturation of insulin 363 
utilization (23) only in fast progressors, as in average progressors total insulin secretion slightly 364 
increased (Figure 2). Whether hepatic or extrahepatic mechanisms underlie these findings cannot be 365 
determined from this study and deserves further investigation.  366 
Our results on TG and HDL effects were partially anticipated by a study of the Genetics of Diabetes 367 
Audit and Research (GoDARTS) (24), where the outcome was the risk of progression to insulin 368 
treatment. The study identified baseline TG and HDL (besides BMI, sex, and age, year and HbA1c 369 
at diagnosis) as independent determinants. A later study on the same data (25), investigating the 370 
baseline determinants of HbA1c progression rate over about 9 years, confirmed an independent 371 
effect of HDL (together with age, BMI and year at diagnosis) but not of TG. The FIELD study in 372 
T2D patients on lifestyle measures only revealed that t e HDL effect on initiation of oral 373 
hypoglycemic agents survives the adjustment for HOMA-IR (26). Compared to previous studies 374 
(24–26) our analysis includes the progression rates of plasma lipid components and baseline MRI 375 
assessment of regional fat. We show that baseline HDL and BMI, and the progression rates of TG 376 
and HDL are associated with HbA1c progression, even after accounting for the effects of he three 377 
main determinants of glucose homeostasis, i.e. insulin ensitivity, β-cell function and insulin 378 
clearance. In the subset of participants with MRI data, baseline visceral fat or liver fat was 379 
independently correlated with HbA1c progression rate, a further novel observation. These findings 380 
suggest that additional lipid-dependent factors contribute to HbA1c deterioration, possible 381 
candidates being fat accumulation in the viscera (with excessive supply of fatty acids to the liver 382 
(27)), liver fat and consequent hepatic insulin resistance (28), or glucose overproduction (29). The 383 
role of visceral/liver fat supports interventions to reduce ectopic fat as a possible way for slowing 384 
future glycemic progression.  385 
 
 
Previous studies have reported an inverse correlation between baseline age and HbA1c progression 386 
(1,4,6,24,25,30). In our analysis, baseline age does n t have a clear independent role in the 387 
multivariable model, most likely because the age range is relatively narrow relative to other studies, 388 
or because the stronger predictors of HbA1c progression are correlated with age. The latter 389 
explanation would suggest that the age univariate effect on glycemic deterioration is indirect. We 390 
do not find a clear sex effect in glycemic deterioration, in agreement with most previous studies 391 
(1,4,6,24,25). 392 
In the multivariable model, baseline HbA1c was independently and inversely correlated with HbA1c 393 
progression rate, in contrast with previous findings (1,4,6,24,30). However, baseline HbA1c was not 394 
significant in the logistic model. The most likely explanation of this finding is regression to the 395 
mean: indeed, a random decrease in baseline HbA1c can produce a higher estimate of HbA1c 396 
progression rate, particularly when the follow-up period is not long, as in our study. Tight glycemic 397 
control, an inclusion criterion, may have enhanced this effect.  398 
This study does not find a relevant role of other variables often associated with glucose control. In 399 
particular, we did not find an effect of smoking status (reported in GPRD (30)), T2D polygenic risk 400 
score (in agreement with GoDARTS (24)), baseline values of diet, physical activity, pancreatic fat, 401 
GLP-1, and glucagon. Several of these variables were not associated with HbA1c progression rate 402 
even in simple correlation analysis (Figure S2). The lack of association for pancreatic fat is 403 
particularly relevant, and contributes to the ongoi discussion on the role of pancreas fat in T2D 404 
management (31).  405 
In spite of the unique extensive phenotyping of our st dy and the consistent results, a significant 406 
limitation is the relatively short follow-up period (3 years). The accuracy of the estimated HbA1c 407 
progression rate over this time frame may be limited, and in a longer time period the factors 408 
contributing to progression may differ. In this study, we could not assess the changes over time of 409 
relevant variables such as regional fat by MRI, diet and physical activity. MRI measurements were 410 
 
 
available only for a subset of subjects. Insulin sesitivity was not derived from the gold standard 411 
euglycemic clamp. As the cohort included only patients of white race, our findings are not 412 
generalizable to other racial/ethnic groups. Causal rel tionships could not be inferred from our 413 
regression analyses. The study of the mechanisms underlying the deterioration of the factors 414 
affecting HbA1c progression, an important aspect to envisage optimal reatment strategies, also 415 
requires further investigation. 416 
In summary, based on the extensively phenotyped cohort f white European diabetic patients of the 417 
DIRECT study, we identified decreasing insulin sensitivity, deteriorating β-cell function, increasing 418 
insulin clearance, high liver or visceral fat, and worsening of the lipid profile as the most important 419 
factors independently associated with HbA1c deterioration in the early phase of the disease. We also 420 
showed that patients with a relatively stable value ov r time of at least one of insulin sensitivity, β-421 
cell glucose sensitivity, or insulin clearance have considerably reduced odds of fast HbA1c increase. 422 
This study contributes to the understanding of the factors underlying diabetes progression, 423 
elucidating the processes that might be targeted for personalized treatments.   424 
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Table 1. Proportion of fast HbA1c progressors with different combinations of stable/deteriorating conditions for GS, OGIS and CLIm progression 546 
rates.  547 
 Condition*        
































* The progression rate thresholds dividing stable and deteriorating traits for OGIS, GS and CLIm are -16.68 ml min-1 m-2 year-1, -4.07 pmol min-1 m-2 mmol-1 l 548 
year-1 and 0.0184 l min-1 m-2 year-1, respectively.  549 
† Two-sided Chi-square test (α=0.05), with Yates continuity correction, on the pro ortion of fast progressors in the row compared to the same proportion in the 550 
last row.  551 
GS: β-cell glucose sensitivity; OGIS: oral insulin sensitivity; CLIm: mixed meal test insulin clearance. 552 
 
 
Figure legends  553 
Figure 1. Variables independently associated with HbA1c progression rate from multivariable linear 554 
analysis. Panel A: all subjects are included in the analysis (625 with all variables), and MRI 555 
measurements are not considered; panel B: only subjects with MRI are included in the analysis (374 556 
with all variables), and MRI measurements are taken into consideration. For each variable, the 557 
figure shows the standardized coefficients ± 95% CI of the effect. Age and HDL were log-558 
transformed. OGIS: oral insulin sensitivity; CLIm: ixed meal test insulin clearance; GS: β-cell 559 
glucose sensitivity; TG: fasting triacylglycerol; HDL: fasting HDL-cholesterol; RS: β-cell rate 560 
sensitivity; progr: progression rate; bas: baseline value; *: p<0.05; **: p<0.01; ***: p<0.001.  561 
Figure 2. Temporal trajectories or baseline values (bar graphs) of HbA1c and other key traits in fast 562 
(red lines) and average (blue lines) progressors. Data are mean ± standard error. Simple 563 
comparisons between fast and average progressors (Wilcoxon rank sum test) are shown for baseline 564 
values (asterisks at month 0) and progression rates( sterisks at month 18). These comparisons may 565 
differ from the results of the multivariable analyses (Figures 2 and 4). Sex is not included in the 566 
figure: males were 42% and 36% in average and fast progressors, respectively (non-significant, 567 
Chi-squared test). HbA1c values at 27 months are not displayed as they werecoll cted in a subgroup 568 
of individuals. In average progressors, HbA1c increases from 46.4±0.2 mmol/mol to 46.7±0.3 569 
mmol/mol; in fast progressors, from 48.9±1.21 mmol/l to 75.7±2.5 mmol/mol. OGIS: insulin 570 
sensitivity; CLIm: mixed meal test insulin clearance; GS: β-cell glucose sensitivity; RS: β-cell rate 571 
sensitivity; TG: fasting triacylglycerol; HDL: fasting HDL-cholesterol; ISRtot: total mixed meal 572 
test insulin secretion; bas: baseline value; *: p<0.05; **: p<0.01; ***: p<0.001.  573 
Figure 3. Odds ratios ± 95% CI from the multivariable logistic analysis of fast vs average HbA1c 574 
progressors. The independent variables are those identified by multivariable linear analysis of 575 
HbA1c progression, excluding MRI variables (N=625, with 32 fast progressors and 593 average 576 
progressors). Age and HDL were log-transformed. Values for sensitivity, specificity and accuracy 577 
 
 
were derived via maximization of balanced accuracy. OGIS: insulin sensitivity; CLIm: mixed meal 578 
test insulin clearance; GS: β-cell glucose sensitivity; TG: fasting triacylglycerol; HDL: fasting 579 
HDL-cholesterol; RS: β-cell rate sensitivity; progr: progression rate; bas: baseline value; AUROC: 580 
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SCIENTIFIC MEMBERS OF THE CONSORTIUM 
 






Examinations were performed in the morning after a 10-hour overnight fast. Participants remained on their usual non-
antidiabetic medications; metformin, if used, was stopped for the 24 hours preceding the study visit and restarted 
immediately after. Anthropometric data, blood pressure, and urine samples were collected. An intravenous cannula was 
inserted into a forearm vein according to local protoc ls. Baseline blood samples were immediately colle ted for 
analysis of glutamic acid decarboxylase and islet antigen-2 antibodies, glucagon-like peptide-1, glucagon, insulin, C-
peptide, HbA1c, and DNA.  
 
Mixed-meal tolerance test (MMTT) 
Before the MMTT, fasting samples for glucose, insulin and C-peptide analysis were collected. The MMTT consisted of 
a 250 ml Fortisip liquid drink (18.4 g carbohydrate per 100 ml) over a period of 2–5 min. Blood samples w re collected 
every 30 min for two hours for subsequent glucose, insulin and C-peptide assays. 
 
Biochemistry assays 
Measurements were performed by a central laboratory. Plasma glucose was measured by the enzymatic colorimetric 
assay GOD-PAP, using Roche MODULAR P analyzers (Hoffmann-La Roche, Basel, Switzerland). Plasma insulin and 
C-peptide were measured by electrochemiluminescence, using Roche E170 analyzers (Hoffmann-La Roche). HbA1c 
was measured by ion-exchange high-performance liquid chromatography, using Tosoh G8 analyzers (Tosoh 
Bioscience, San Francisco, CA, USA). 
Aspartate aminotransferase (AST) and alanine aminotra sferase (ALT) were measured by UV absorbance without 
pyridoxal phosphate activation. Gamma-glutamyl transferase (GGT) was measured by enzymatic colorimetric assay. 
Serum creatinine and albumin were measured with the Creatinine Jaffé method and the bromocresol green m thod, 
respectively. Cholesterol was measured by enzymatic colorimetric methods, HDL-cholesterol was measured directly 
using PEG-modified enzymes and dextran sulphate, triacylglycerol was measured by quantitative determination with 
glycerol blanking. AST, ALT, GGT, serum creatinine and albumin, cholesterol, HDL-cholesterol and triacylglycerol 
were measured using a Roche MODULAR P analyzer (Roche Diagnostics, Indianapolis, IN, USA). LDL-cholestrol 
was calculated from the Friedewald formula. 
Intact proinsulin was measured using the TECO Medical Intact Proinsulin ELISA kit in use on the Dynex DS2 analyzer. 
Glucagon, glutamic acid decarboxylase (GAD) and islet antigen-2 antibodies (IA-2) were measured using a DS2 Elisa 
robot, Dynex technologies. 
Plasma samples for glucagon-like peptide-1 (GLP-1) measurement were collected in P800 tubes (Becton Dickinson, 
Wokingham, UK) to prevent intrinsic proteolysis. Intact GLP-1 was measured using MSD GLP-1 active kit (product 
code K150JWC; Meso Scale Diagnostics, Rockville, MD, USA). Total GLP-1 was assayed using MSD GLP-1 total ki  
(product code K150JVC; Meso Scale Diagnostics). 
Each biochemical assay was performed using validated standard methods. Reference samples were included in all 
procedures to control for inter-assay variation, and the laboratory regularly participated in international external quality 
assessment schemes. 
Body composition 
Body mass index (BMI) was calculated as weight divided by height squared, and waist circumference was measured at 
the level of the umbilicus at mid-respiration. The hepatic steatosis index (HSI) was calculated as described previously 
(1). 
 
Abdominal MRI  
The volume of adipose tissue was measured using MRI, as described elsewhere (2). Total abdominal adipose tissue was 
separated into intra-abdominal adipose tissue, also referred to as “visceral” fat, and abdominal subcutaneous adipose 
tissue. Liver and pancreas fat and iron were derived simultaneously using a multiecho MRI technique (2–4). 
 
Dietary data  
Self-reported dietary intake was assessed by 24-hour multi-pass method, using food habit and 24-hour recall 
questionnaires. Nutritional analysis was undertaken usi g Dietplan-7 software (Forestfield Software Ltd, Horsham, 
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UK). All diet coders were trained by a lead research dietician/nutritionist using a study specific operational manual 
protocol. Detailed description of the coding and diet analysis protocol are reported elsewhere (5).   
Dietary patterns were assessed in concordance with the WHO dietary guidelines using the validated “Healthy Diet 
Indicator” (HDI) (6); a higher HDI score indicates a more favorable diet. The score was calculated from the dietary 
intakes of all food and drink consumed except alcohol, which was analyzed separately. 
 
Physical activity intensity and sedentary behaviour 
Participants were fitted with a wrist-worn triaxial accelerometer (ActiGraph GT3X+; Actigraph LLC, Pensacola, FL, 
USA) for measurement of physical activity, sedentary behavior and sleep over 10 days. The monitor was fitted to the 
participant’s non-dominant wrist using an adjustable strap. The participant was requested to wear the monitor 
continuously for 10 days to allow habitual uninterrupted measures of both sleep and physical activity. The monitor was 
set to record at 30 Hz with the manufacturer’s sleep mode disabled. High-pass-filtered vector magnitude (hpfVM) was 
derived as described elsewhere (7). In this analysis, we used the 10-day mean hpfVM and the percentage of hpfVM 
values ≤ 48 mg as measures of physical activity intensity and sedentary behavior. 
 
Type 2 diabetes (T2D) polygenic risk score 
A T2D polygenic risk score was computed from the 403 single-nucleotide polymorphisms (SNPs) and the respective 
effect sizes reported for T2D in Mahajan et al. (8) The individual score values were obtained by summing up the 
number of risk alleles at each locus multiplied by its effect size. 
 
Additional questionnaires 
Questionnaire data were collected on alcohol consumption, smoke habits, family history of diabetes andmedication 
history. 
 





Area under the curves and mean values 
Areas under the curve (AUC) of several MMTT variables were computed according to the trapezoidal rule and mean 
values as AUC/time interval. 
 
Mathematical modelling of β-cell function 
From MMTT glucose and C-peptide, the following β-cell function parameters were calculated by mathematical 
modelling (9): glucose sensitivity (GS), i.e., the slope of the relationship between glucose concentration nd insulin 
secretion rate; rate sensitivity (RS), marker of early insulin release; insulin secretion rate at 8 mmol/l glucose (ISRstd); 
potentiation factor ratio (PR), the ratio between the potentiation factor at 2- and 0-hours, ; total insulin secretion 
(ISRtot), i.e., the AUC of insulin secretion during the whole MMTT. Insulin secretion rate was calculated from C-
peptide using Van Cauter’s C-peptide model (10). 
 
Insulin clearance 
Fasting insulin clearance (CLIb) was calculated as the ratio between fasting insulin secretion and fasting insulin 
concentration. The MMTT insulin clearance (CLIm) was calculated as the ratio of the AUCs of insulin secretion and 
insulin concentration during the MMTT.  
 
Mathematical modelling of HbA1c progression rate 
The HbA1c trajectories were described with a conditional linear mixed-effect model (11). The conditional approach 
employs a linear transformation of the data to derive a longitudinal and a cross-sectional component, which are 
orthogonal. The transformation makes modelling of the longitudinal component independent of the cross-sectional 
effects: the former is relevant for quantification f HbA1c progression rate, while the latter are potential confounders 
that need not to be considered in the conditional approach. In particular, the approach eliminates possible spurious 
correlations between the longitudinal parameters and baseline HbA1c, which may arise if baseline HbA1c is not 
accurately modelled. 
The longitudinal HbA1c component was described as the sum of the following terms:  
• a proportional effect of time, described by the parameter ri, where i represents a specific individual, 
represented as a random variable with a normal distribution; 
• a proportional effect of BMI; 
• a linear effect of the metformin dose, expressed as percentage of a maximal dose of 3 grams; 
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• a linear effect of the cumulative dose for the other antidiabetic drugs (insulin excluded), expressed as sum of 
the percentages of the maximum dose of each drug; 
• a constant effect of insulin treatment; 
• a proportional effect of delay in HbA1c assay, i.e. of the difference between the time of measurement and the 
time of sample collection; 
• a residual error εik, where k refers to the time point, represented as a random variable from a normal 
distribution with zero mean. 
The insulin and BMI effects were constrained to be negative and positive, respectively. The linear effects of the 
treatment dose were modelled as 0 for dose=0, and as a+b·dose for dose>0, where a and b were different for metformin 
and the other antidiabetic drugs and were constrained to be negative. Maximum doses for antidiabetic drugs different 
from metformin and insulin were fixed to the values in Table S3. A medication was considered effective at a given time 
if it was taken at least 30 days before. 
The ri parameter represents the HbA1c underlying progression rate, adjusted for changes in BMI and antidiabetic 
treatments. 
The model parameters were estimated using Monolix 2016 R1(12), which implements the SAEM algorithm for 
estimation of mixed-effect models. In a first step, the software identifies mean and standard deviation of the population 
distribution of the model parameters with inter-indivi ual variability (in our case just r). In the second step, the software 
computes the individual estimates of the parameters (in our case ri) by simultaneously fitting the data and using the 
previously estimated distributions as priors (maximum a posteriori estimation). 
The parameter estimates of the HbA1c progression model are reported in Table S4. The BMI and treatment effects were 
concordant with what shown in the literature(13), considering the low baseline HbA1c values in this study (6.41±0.53 %, 
46.5±5.8 mmol/mol, mean ± standard deviation). 
 
Progression rates for other traits 
The progression rates for all other traits were derived in the same way as for HbA1c, but without including the effect of 
treatments and assay delay. The BMI effect was included only in the models for OGIS and QUICKI. The BMI effects 
on OGIS and QUICKI progression rates were -8.68±11% (estimate±relative standard error) ml min-1 kg-1 and -
0.00157±9% m2 kg-1, respectively. 
 
On the multivariable analyses 






Progression rates of HbA1c and other traits 
HbA1c was measured at two visits in 6% of participants, a  three visits in 15% of participants, at four visits in 75% of 
participants, and at five visits in 4% of participants. 
In 50% of the subjects, T2D was managed via lifestyl  only along the whole study.  
The estimates of the progression rates for HbA1c, adjusted for changes in BMI and in diabetes medications, and for the 
other traits are reported in Figure S1 (histogram for HbA1c progression rates only) and Table S5. 
 
Variables associated with HbA1c progression rate 
The pairwise associations between HbA1c progression rate and baseline values and progression rates of the investigated 
traits are shown in Figure S2. 
The standardized coefficients and the p values of the independent variables included in the multivariable linear analysis 
of HbA1c progression rate are shown in Table S6. The table presents different regression models, all adjusted for sex, 
baseline age and center, and considering different subsets of subjects, based on the availability of different subsets of 
variables. The models described  include those with a unique independent variable (models named “-1”), a model with 
the adjustment variables only (model “0”), and models including or excluding the effects of baseline liv r fat or visceral 
fat, and the effects of baseline BMI and fasting HDL-cholesterol, found to have non-significant effects once visceral or 
liver fat is included in the analysis. The models presented in the main text are numbered “1” and “9”. 
In the multivariable linear analysis, the indices of insulin sensitivity OGIS and QUICKI, as well as HOMA-IR (14), 
Stumvoll (15) and Matsuda (16) indices (data not shwn), were interchangeable in terms of overall analysis results, with 
OGIS producing the best performance (adjusted R2 0.38 vs 0.33, 0.37, 0.28 and 0.29, respectively; N = 625). 
 
Variables associated with fast vs average HbA1c progression 
The logistic analysis reported in the main text defines fast vs average progressors based on a threshold on HbA1c 
progression rate that clearly separate the two groups (0.255 %/year, 2.79 mmol mol-1 year-1, Figure S1). We found that 
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this threshold corresponds to (q50 - q1) + q50, where q1 and q50 are the 1st and 50th quantiles of the distribution of 
individual HbA1c progression rates. The use of lower thresholds allows the identification of larger sets of fast 
progressors. In particular, using the 2nd, 5th or 10th quantile instead of the 1st quantile in the formula, thresholds of 0.200, 
0.143 or 0.121 %/year (2.19, 1.56 or 1.32 mmol mol-1 year-1), respectively, are obtained, with a corresponding number 
of fast progressors of  N=61, N=110 or N=131 subjects, respectively, instead of N=33 (Figure S1). 
With the lower thresholds, discrimination capacity, sensitivity, specificity and accuracy of the logistic model described 
in the main text remain very similar (Figure S3). The effects of the independent variables of the logistic model are also 
essentially unaffected (Figure S3). In all cases, it appears that stronger deterioration and a lower baseline value of OGIS 
and GS, and CLIm increase are independently associated with fast progression. Minor differences are th following: the 
effect of HDL reduction is significant with all thresholds apart from 0.200 %/year; the effect of baseline HDL is 
significant only using thresholds 0.143 and 0.121 %/year; the effect of baseline CLIm is significant oly with the lowest 
threshold (0.121 %/year); the effect of baseline HbA1c is significant with all lower thresholds but not with the original 
one. 
The percentage of patients without diabetes medications along the whole study was higher in average than in fast 
progressors (51% vs 30%, p=0.021 from two-sided Chi-square test with α=0.05). At baseline, the percentages of fast 
progressors and of average progressors treated with metformin were not different: 39.4% [24.7-56.3%, 95% CI] vs 
33.9% [30.5-37.5%], respectively (p = 0.64). At the last visit, the percentage of fast progressors treated with any 
diabetes medication, 66.7% [49.6-80.2%], was somewhat higher than the percentage of average progressors treated with 
any diabetes medication, 47.5% [43.8-51.2%] (p = 0.048). This difference was driven by a larger use of diabetes 
medications other than metformin or insulin in fast progressors (30.3% [17.4-47.3%] vs 5.0% [3.6-6.9%], p = 3E-
8). Again at the last visit, the number of patients treated with insulin (seven average progressors) wa  too low to derive 
any trustworthy comparison between percentages of fast and average progressors treated with insulin (0.0% [0.0-10.4%] 
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Table S2. Subjects’ baseline traits. 
Trait  Abbreviation Baseline value* N 
Age (years) age 62±8 732 
Sex (males) - 58 732 
Body mass index (kg/m2) BMI 30.4±4.9 732 
Waist circumference (cm) waist 103±13 727 
Systolic blood pressure (mm Hg) BPsys 131±16 621 
Diastolic blood pressure (mm Hg) BPdia 75±10 621 
Type 2 diabetes family history - 39 682 
On metformin† - 34 732 
Metformin dosage for subjects on metformin (g)† - 1.0±0.5 732 
HbA 1c (%, mmol/mol) HbA1c 6.41±0.53, 46.5±5.8 728 
Fasting glucose (mmol/l)† gb 7.1±1.4 731 
Fasting insulin (pmol/l)† ib 106±69 730 
Mean MMTT glucose (mmol/l)† gm 9.3±2.1 730 
Mean MMTT insulin (pmol/l) † im 459±279 730 
Fasting insulin secretion (pmol min-1 m-2)† ISRb 136±48 730 
Total MMTT insulin secretion (nmol/m 2)† ISRtot 44±15 730 
Fasting triacylglycerol (mmol/l) TG 1.51±0.78 732 
Fasting total cholesterol (mmol/l) CHO 4.22±1.15 732 
Fasting LDL-cholesterol (mmol/l) LDL 2.34±0.95 727 
Fasting HDL-cholesterol (mmol/l) HDL 1.18±0.39 732 
Aspartate aminotransferase (U/l) AST 25.6±11.1 732 
Alanine aminotransferase (U/l) ALT 26.2±13.8 732 
AST/ALT ratio (unitless)  AST/ALT 1.09±0.48 732 
Gamma-glutamyl transferase (U/l) GGT 51±71 732 
Serum creatinine (µmol/l) SCr 74.7±17.9 732 
Serum albumin (g/l)  ALB 39.7±2.6 165 
Fasting intact glucagon-like peptide-1 (pg/ml) iGLP1 0.64±0.91 725 
Fasting total glucagon-like peptide-1 (pg/ml) tGLP1 9.5±9.3 724 
1-h total glucagon-like peptide-1 (pg/ml) tGLP1.60 19±16 722 
Fasting glucagon (pg/ml) GLG 111±52 704 
1-h glucagon (pg/ml) GLG.60 107±39 717 
2-h glucagon (pg/ml) GLG.120 103±25 184 
1-h GLP-1 increment (pg/ml) GLP1inc.60 9.8±12.7 718 
1-h glucagon increment (pg/ml) GLGinc.60 -3±52 693 
2-h glucagon increment (pg/ml) GLGinc.120 -6±33 183 
1-h intact proinsulin (pmol/l)  proins.60 22±14 359 
1-h intact proinsulin to insulin ratio (unitless) proins/ins.60 0.05±0.04 358 
Insulin sensitivity (ml min -1 m-2) OGIS 300±74 728 
Fasting insulin sensitivity (unitless) QUICKI 0.136±0.014 730 
β-cell glucose sensitivity (pmol min-1 m-2 mmol-1 l ) GS 85±56 714 
β-cell rate sensitivity (pmol m-2 mmol-1 l) RS 1138±1102 714 
Insulin secretion rate at 8 mmol/l glucose (pmol min-1 m-2) ISRstd 228±135 714 
Potentiation factor ratio (unitless) PR 1.4±0.6 713 
Fasting insulin clearance (l min-1 m-2) CLIb 1.60±1.02 730 
MMTT insulin clearance (l min-1 m-2) CLIm 0.93±0.30 730 
Hepatic steatosis index (unitless) HSI 41.5±5.9 730 
Fatty liver index (unitless) FLI 67±27 725 
Type 2 diabetes polygenic risk score (unitless) PRS 25.2±0.7 732 
Liver fat (%)  liver fat 9±7 480 
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Trait  Abbreviation Baseline value* N 
Liver iron content (mg/g tissue) liver iron 1.6±0.5 486 
Pancreas fat (%) pancreas fat 12±8 488 
Pancreas iron content (mg/g tissue) pancreas iron 1.4±0.5 509 
Intra -abdominal adipose tissue (l) visceral fat 5.5±2.2 429 
Abdominal subcutaneous adipose tissue (l) subcutaneous fat 8.0±3.7 429 
Physical activity intensity (mg) PA 35±10 674 
Sedentary behavior (% of time) SED 83±4 674 
Smoking habits (%, current, ex, never) - 13, 50, 37 732 
Average alcohol consumption (%, regularly, occasionally, never) - 58, 25, 17 732 
24-h energy intake (kcal) - 1828±625 644 
24-h protein intake (g) - 89±35 644 
24-h fat intake (g) - 73±34 644 
24-h saturated fat intake (g) - 26±14 644 
24-h added sugars intake (g) - 65±40 644 
24-h carbohydrate intake (g) - 221±91 644 
24-h energy intake-adjusted non‐starch polysaccharides (g/kcal) - 8.7±3.3 644 
24-h energy intake-adjusted fruit & vegetables (g/kcal) - 227±145 644 
24-h energy intake-adjusted wholegrains (g/kcal) - 26±22 644 
24-h energy intake-adjusted fish (g/kcal) - 20±39 644 
24-h energy intake-adjusted red meat (g/kcal) - 46±49 644 
24-h percentage of total energy intake from protein (%) - 20±6 644 
24-h percentage of total energy intake from fat (%)  - 36±9 644 
24-h percentage of total energy intake from saturated fat (%)  - 13±5 644 
24-h percentage of total energy intake from added sugars (%) - 19±8 644 
24-h percentage of total energy intake from carbohydrate (%) - 49±11 644 
Healthy diet indicator  HDI 4.7±2.6 644 
Healthy diet indicator quartiles (% in quartiles 1, 2, 3 and 4) - 23, 25, 26, 26 644 
* Data are mean ± standard deviation of the inter-indiv dual distribution, or percentage. 
† Trait not included in the stepwise multivariable analyses. 
MMTT: mixed meal test. 
 
 
Table S3. Maximum doses for antidiabetic drugs different from insulin. 
Drug Max Dose (mg) Weekly (W) or Daily (D) 
Acarbose 600 D 
Metformin  3000 D 
Dapagliflozin 10 D 
Empagliflozin 25 D 
Alogliptin 25 D 
Sitagliptin 100 D 
Dulaglutide 1.5 W 
Liraglutide 1.8 D 
Gliclazide 320 D 
Glimepiride 4 D 
Glipizide 20 D 
Tolbutamide 2000 D 
 
 
Table S4. Parameter estimates of the HbA1c progression model. 
Parameter Estimate RSE (%) 
r (%/year, mmol mol-1 year-1) 0.0627, 0.685* 17 
BMI effect (% kg-1 m-2, mmol mol-1 kg-1 m-2) 0.131, 1.43 8 
Metformin effect: a (%, mmol/mol) -0.0942, -1.03 74 
Metformin effect: b (%, mmol/mol) -0.00145, -0.0159 101 
Metformin effect with 100% dose (%, mmol/mol) -0.240, -2.62 - 
Other antidiabetic treatment effect: a (%, mmol/mol) -0.0970, -1.06 153 
Other antidiabetic treatment effect: b (%, mmol/mol) -0.00161, -0.0176 138 
Other antidiabetic treatment effect with 100% dose (%, mmol/mol) -0.258, -2.82 - 
Insulin effect (%, mmol/mol) -0.0970, -1.06 205 
Assay delay effect (%/day, mmol mol-1 day-1) -0.00047, -0.00516 19 
RSE: relative standard error of the estimate. 




Table S5. Estimates of the progression rates of the investigated traits. 





Body mass index (kg m-2 year-1) BMI -0.0089±0.52 -0.058,0.040 -0.03 732 
Waist circumference (cm year-1) waist 0.54±1.3 0.37,0.71 0.52 719 








Total MMTT insulin secretion (nmol m -2 year-1)‡ ISRtot 0.44±2.4 0.13,0.75 1.00 653 
Fasting triacylglycerol (mmol l-1 year-1) TG 0.038±0.14 0.016,0.060 2.50 719 
Fasting total cholesterol (mmol l-1 year-1) CHO -0.012±0.22 -0.039,0.015 -0.28 719 
Fasting LDL-cholesterol (mmol l-1 year-1) LDL -0.046±0.18 -0.070,-0.023 -1.94 713 
Fasting HDL-cholesterol (mmol l-1 year-1) HDL 0.016±0.040 0.009,0.023 1.36 719 
Aspartate aminotransferase (U l-1 year-1) AST 1.2±3.6 0.77,1.63 4.77 719 
Alanine aminotransferase (U l-1 year-1) ALT 0.53±10 -0.39,1.45 2.01 719 
AST/ALT ratio (year -1) AST/ALT 0.039±0.04 0.024,0.054 3.61 719 
Serum creatinine (µmol l-1 year-1) SCr -0.21±1.2 -0.58,0.16 -0.29 719 
Insulin sensitivity (ml min -1 m-2 year-1) OGIS -8.5±19 -10.7,-6.3 -2.82 649 
Fasting insulin sensitivity (year-1) QUICKI -0.0013±0.0025 -0.0016,-0.0010 -0.95 653 
β-cell glucose sensitivity (pmol min-1 m-2 mmol-1 l 
year-1) 
GS -1.9±5.0 -3.4,-0.4 -2.19 653 
β-cell rate sensitivity (pmol m-2 mmol-1 l year-1) RS -22±98 -57,13 -1.91 653 
Insulin secretion rate at 8 mmol/l glucose (pmol 
min-1 m-2 year-1) 
ISRstd -5.2±19 -8.5,-1.9 -2.29 653 
Potentiation factor ratio (year-1) PR -0.0035±0.11 -0.023,0.016 -0.25 652 
Fasting insulin clearance (l min-1 m-2 year-1) CLIb -0.039±0.34 -0.070,-0.008 -2.46 653 
MMTT insulin clearance (l min-1 m-2 year-1) CLIm -0.00069±0.046 -0.0072,0.0058 -0.07 653 
Hepatic steatosis index (year-1) HSI -0.31±0.68 -0.40,-0.22 -0.74 717 
* Data are mean ± standard deviation of the inter-indiv dual distribution, and are expressed as units/year (e.g. %/year or 
mmol mol-1 year-1 for HbA1c). 
† Ratio between mean progression rate and mean baseline va ue (from Table S2), as percentage per year.  
‡ Progression rate not included in the stepwise multivariable analyses. 




Table S6. Standardized coefficients (with p values as superscripts) and adjusted R2 from multivariable linear analysis of HbA1c progression rate. 





GS progr TG progr 
HDL 
progr 








-1 - - -0.24*** 0.16*** -0.23*** 0.25*** -0.11** -0.070.07 -0.11** -0.11** 0.020.58 -0.060.13 0.15*** -0.18*** 0.27*** 0.19*** - 625* 
0 -0.040.61 -0.15*** - - - - - - - - - - - - - - 0.04 625 
1 0.120.08 -0.030.31 -0.57*** 0.28*** -0.25*** 0.15*** -0.14*** -0.09* -0.52*** 0.21*** -0.20*** -0.14*** 0.10** -0.10* - - 0.38 625 
2 0.21* -0.08* -0.61*** -0.08* -0.27*** 0.30*** -0.11* 0.13** -0.53*** 0.22*** -0.22*** -0.15** 0.09 0.07 -0.050.37 - - 0.40 
407 
(liver fat bas 
available) 
3 0.150.10 -0.060.16 -0.60*** -0.12** -0.28*** 0.25*** -0.14** 0.17*** -0.57*** 0.22*** -0.20*** -0.17** 0.060.24 -0.110.05 - - 0.40 
373 
(visceral fat bas 
available) 
4 0.18* -0.080.06 -0.59*** -0.08* -0.28*** 0.30*** -0.11* 0.13** -0.49*** 0.24*** -0.24*** -0.16** 0.08 0.10 -0.030.51 - 0.10* 0.40 407 
5 0.25* -0.080.06 -0.58*** -0.12** -0.27*** 0.24*** -0.13** 0.17*** -0.55*** 0.24*** -0.21*** -0.16** 0.010.87 -0.110.06 0.14* - 0.41 373 
6 0.140.14 -0.080.7 -0.63*** 0.25*** -0.26*** 0.17*** -0.10* -0.10* -0 .54*** 0.21*** -0.21*** -0.16** - - - 0.12* 0.40 
320 (both visceral 
fat bas and liver fat 
bas available) 
7 0.26** -0.11* -0.63*** 0.25*** -0.25*** 0.16*** -0.080.10 -0.11* -0.56*** 0.23*** -0.20*** -0.14* - - 0.16** - 0.41 
320 (both visceral 
fat bas and liver fat 
bas available) 
8 0.17* -0.09* -0.61*** 0.30*** -0.27*** 0.13** -0.10* -0.080.06 -0.50*** 0.19*** -0.23*** -0.16** - - - 0.11* 0.40 408 
9 0.19* -0.09* -0.62*** 0.24*** -0.16** 0.18*** -0.10* -0.12** -0.56*** 0.21*** -0.20*** -0.16** - - 0.15** - 0.40 374 
Model (-1): HbA1c progression rate = sex + age bas + center + variable (each column represents a specific model, and the various models are given in a unique row for sake of 
clarity). 
Model (0): HbA1c progression rate = sex + age bas + center. 
Model (1): HbA1c progression rate = sex + age bas + center + OGIS progr + CLIm progr + GS progr + TG progr + HDL progr + RS progr + OGIS bas + CLIm bas + HbA1c bas + 
GS bas + BMI bas + HDL bas. This is the model in Figure 1, panel A. 
Model (2): Model (1), with different N (see last column). 
Model (3): Model (1), with different N (see last column). 
Model (4): Model (1) + liver fat bas. 
Model (5): Model (1) + visceral fat bas. 
Model (6): HbA1c progression rate = Sex + Age bas + center + OGIS progr + CLIm progr + GS progr + TG progr + HDL progr + RS progr + OGIS bas + CLIm bas + HbA1c bas 
+ GS bas + liver fat bas. 
Model (7): HbA1c progression rate = Sex + Age bas + center + OGIS progr + CLIm progr + GS progr + TG progr + HDL progr + RS progr + OGIS bas + CLIm bas + HbA1c bas 
+ GS bas + visceral fat bas. 
Model (8): Model (6), with different N (see last column). 
Model (9): Model (7), with different N (see last column). This is the model in Figure 1, panel B. 
* N = 320 for columns Visceral fat bas and Liver fat bas. 
OGIS: insulin sensitivity; CLIm: mixed meal test insulin clearance; GS: β-cell glucose sensitivity; TG: fasting triacylglycerol; HDL: fasting HDL-cholesterol; RS: β-cell rate 




Figure S1. Distribution of the estimated individual progression rates of HbA1c (N=732), adjusted for changes in BMI 
and anti-diabetic medications. Panel A: histogram. Panel B: quantile-quantile plot. In both panels, four straight solid 
lines show four different thresholds used to split subjects into average and fast progressors. The thresholds were 
computed as (q50 – qn) + q50, where qn and q50 are the nth and 50th quantiles of the distribution: the threshold used in the 
main text (n=1) is shown in red, three less conservative thresholds (n=2, 5 and 10) are shown in green, light blue and 




Figure S2. Pairwise correlation matrixes of the variables considered in this study (diet variables excluded as none was 
associated with HbA1c progression rate). Panel A: pairwise correlations among baseline values of the traits and HbA1c 
progression rates. Panel B: pairwise correlations among all the estimated progression rates. Correlations with HbA1c 
progression rates are displayed in the first columns of both panels. Fill color represents Spearman correlation 
coefficient, where positivity is denoted by red fill, negativity by blue fill, and magnitude by color intensity (see color 
bars) and by elliptic shape. BMI: body mass index; BPsys: systolic blood pressure; BPdia: diastolic blood pressure; gb: 
fasting glucose; ib: fasting insulin; gm: mean mixed meal test (MMTT) glucose; im: mean MMTT insulin; ISRb: fasting 
insulin secretion (ISR); ISRtot: total MMTT insulin secretion; TG: fasting triacylglycerol; CHO: fasting total 
cholesterol; LDL: fasting LDL-cholesterol; HDL: fasting HDL-cholesterol; AST: aspartate aminotransferas ; ALT: 
alanine aminotransferase; AST/ALT: AST/ALT ratio; GGT: gamma-glutamyl transferase; SCr: serum creatinine; ALB: 
serum albumin; iGLP1: fasting intact glucagon-like peptide-1 (GLP-1); tGLP1: fasting total GLP-1; tGLP1.60: 1-h total 
GLP-1; GLG: fasting glucagon; GLG.60: 1-h glucagon; GLG.120: 2-h glucagon; GLP1inc.60: 1-h GLP-1 increment; 
GLGinc.60: 1-h glucagon increment; GLGinc.120: 2-h glucagon increment; proins.60: 1-h intact proinsulin; 
proins/ins.60: 1-h intact proinsulin to insulin ratio; OGIS insulin sensitivity; QUICKI: fasting insulin sensitivity; GS: β-
cell glucose sensitivity; RS: β-cell rate sensitivity; ISRstd: insulin secretion rate at 8 mmol/l glucose; PR: potentiation 
factor ratio; CLIb: fasting insulin clearance; CLIm: MMTT insulin clearance; HSI: hepatic steatosis index; FLI: fatty 
liver index; PRS: polygenic risk score; PA: physical activity intensity; SED: sedentary behavior; progr: progression 





Figure S3. Odds ratios ± 95% confidence interval (CI) from the multivariable logistic analysis of fast vs average HbA1c 
progressors, using different thresholds between the two groups. The independent variables are those identified by 
multivariable linear analysis of HbA1c progression, excluding MRI variables (N=625). Panels A to D refer to 
progressively lower thresholds as shown in Figure S1 and in the summary table at the bottom. Age and HDL were log-
transformed. Values for sensitivity, specificity and accuracy were derived via maximization of balanced accuracy. 
OGIS: insulin sensitivity; CLIm: mixed meal test insulin clearance; GS: β-cell glucose sensitivity; TG: fasting 
triacylglycerol; HDL: fasting HDL-cholesterol; RS: β-cell rate sensitivity; BMI: body mass index; progr: p ogression 
rate; bas: baseline value; AUROC: area under the rec iv r operating curve; *: p<0.05; **: p<0.01; ***: p<0.001.  
